- Report
- October 2024
- 195 Pages
Global
From €3365EUR$3,545USD£2,839GBP
€3739EUR$3,939USD£3,154GBP
- Report
- March 2025
- 94 Pages
Global
From €5316EUR$5,600USD£4,484GBP
- Report
- February 2025
- 200 Pages
Global
From €4262EUR$4,490USD£3,595GBP
- Report
- February 2025
- 150 Pages
Global
From €4604EUR$4,850USD£3,884GBP
- Report
- February 2025
- 180 Pages
Global
From €4272EUR$4,500USD£3,603GBP
- Report
- November 2024
- 600 Pages
Global
From €3133EUR$3,300USD£2,643GBP
- Report
- October 2024
- 187 Pages
Global
From €3365EUR$3,545USD£2,839GBP
€3739EUR$3,939USD£3,154GBP
- Report
- January 2025
- 100 Pages
Global
From €5649EUR$5,950USD£4,765GBP
- Report
- December 2024
- 100 Pages
Global
From €5649EUR$5,950USD£4,765GBP
- Report
- March 2025
- 171 Pages
Global
From €5316EUR$5,600USD£4,484GBP
- Report
- March 2025
- 250 Pages
Global
From €5174EUR$5,450USD£4,364GBP
- Report
- March 2025
- 200 Pages
Global
From €4262EUR$4,490USD£3,595GBP
- Report
- February 2025
- 200 Pages
Global
From €4262EUR$4,490USD£3,595GBP
- Report
- August 2024
- 150 Pages
Global
From €4604EUR$4,850USD£3,884GBP
- Report
- June 2024
- 300 Pages
Global
From €2326EUR$2,450USD£1,962GBP
- Report
- May 2024
- 139 Pages
Global
From €6170EUR$6,499USD£5,204GBP
- Report
- May 2024
- 130 Pages
Global
From €6170EUR$6,499USD£5,204GBP
- Report
- May 2024
- 140 Pages
Global
From €6170EUR$6,499USD£5,204GBP
- Drug Pipelines
- September 2024
- 247 Pages
Global
From €7547EUR$7,950USD£6,366GBP
- Report
- April 2024
- 30 Pages
Global
From €2611EUR$2,750USD£2,202GBP

Somatostatin Analogs are a class of drugs used in the treatment of oncology. They are used to inhibit the release of hormones, such as growth hormone, which can be overproduced in certain types of cancer. Somatostatin Analogs are used to treat a variety of cancers, including neuroendocrine tumors, carcinoid tumors, and pancreatic islet cell tumors. They are also used to treat acromegaly, a condition caused by excessive growth hormone production. Somatostatin Analogs are administered either intravenously or subcutaneously, depending on the type of cancer being treated.
The Somatostatin Analogs market is a rapidly growing segment of the oncology drugs market. It is driven by the increasing prevalence of cancer, as well as the development of new and improved drugs. The market is expected to continue to grow in the coming years, as more drugs are developed and approved for use.
Some of the major companies in the Somatostatin Analogs market include Novartis, Pfizer, Merck, and Sanofi. Show Less Read more